Skip to content

Selank Stacking Guide: Best Combinations & Protocols (2026)

From Peptidepedia, the trusted peptide wiki.

Stacking

Selank's multi-target mechanism makes it a logical candidate for combination with compounds that address complementary pathways. The most established combination is with Semax, its sister peptide from the same Russian research program.

Selank + Semax

The most commonly discussed stack in the nootropic community. Selank provides anxiolytic stabilization through GABAergic and enkephalin pathways; Semax provides cognitive stimulation through dopaminergic activation and BDNF upregulation. For a detailed comparison of both peptides, see Selank vs Semax. Together, they create a balanced profile of enhanced focus without anxiety, calm alertness rather than jittery stimulation or sedated calm. Both are administered intranasally on compatible schedules. Russian clinicians have reportedly used this combination, though formal combination studies are limited.

Selank + Noopept

Noopept (N-phenylacetyl-L-prolylglycine ethyl ester) is a synthetic nootropic that also modulates BDNF and NGF expression. Combined with Selank, the rationale is additive neurotrophin support plus anxiolysis. Both can be administered intranasally.

Selank + Magnesium L-Threonate

Magnesium L-threonate crosses the blood-brain barrier and enhances GABAergic function through a different mechanism than Selank (direct NMDA receptor modulation). The combination may provide complementary anxiolytic support through convergent but distinct pathways.

Selank + Adaptogens (Ashwagandha, Rhodiola)

Herbal adaptogens that modulate the hypothalamic-pituitary-adrenal axis may complement Selank's neurotransmitter-level anxiolysis by reducing upstream cortisol signaling. No formal interaction studies exist.

General Stacking Caution: Formal drug interaction data for Selank is effectively nonexistent outside of the diazepam synergy study. Establishing individual response to Selank alone before introducing additional compounds is advisable.

Frequently Asked Questions

Selank has a notably clean side effect profile. The most commonly reported effects are mild nasal irritation, transient stinging, or dryness at the administration site. Unlike benzodiazepines, Selank does not cause sedation, cognitive impairment, tolerance, or dependence in published clinical data.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Zozulya AA, Sizov SV, Syrtsev AV. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48.
  2. Kasian A, Kolomin T, Andreeva L, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol. 2017;2017:5091027.
  3. Zozulya AA, Kost NV, Sokolov OY, et al. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):17-22.
  4. Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;7:31.
  5. Andreeva LA, Kolomin TA, Myasoedov NF. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Front Pharmacol. 2017;8:89.
  6. Kolomin T, Shadrina M, Slominsky P, et al. Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank. Regul Pept. 2011;170(1-3):18-23.
  7. Kolomin T, Morozova M, Shadrina M, et al. The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. Mol Immunol. 2014;58(1):50-55.
  8. Myasoedov NF, Andreeva LA, Grigorjeva ME, et al. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018;25(10):914-923.
  9. World Anti-Doping Agency. The 2026 Prohibited List: International Standard.
  10. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”